Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2016-09-14 Share Issue/Capital Cha…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Theradiag carried out a capital increase fully subscribed by its Chinese partner, HOB Biotech. Key phrases include 'capital increase fully subscribed', 'issue 741,056 new shares', and details about the subscription price and resulting share capital. This activity directly relates to changes in the company's financing and capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an interim report (IR), or a formal regulatory filing like a 10-K.
2016-09-14 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated September 5, 2016, announcing a business development: Janssen Biotech choosing LISA TRACKER® for a patient monitoring program. It details an agreement involving Theradiag, Janssen Biotech, and Miraca Life Sciences regarding licensing and supply of raw materials. This type of announcement, focusing on strategic partnerships, licensing deals, or significant commercial updates that are not standard periodic financial reports (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since it is a specific announcement about a business arrangement and not a formal financial statement, management change, or dividend notice, the most appropriate category is the general Regulatory Filings fallback (RNS), as it is a formal communication to the market about a material event, even if it's not a standard SEC form. It is too detailed to be a simple Report Publication Announcement (RPA) and does not fit any other specific category like M&A (TAR), Capital (CAP), or Earnings (ER).
2016-09-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated September 5, 2016, announcing a partnership where Theradiag's LISA TRACKER® tests will be used by Janssen Biotech in a patient monitoring program for Remicade®. This announcement details a business development, a strategic partnership, and its implications for sales/royalties. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a specific announcement regarding business operations and potential revenue streams, which fits best under a general regulatory announcement or business update category. Since it is a press release announcing a business development rather than a specific financial report or mandatory filing, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard, material announcements, although 'Capital/Financing Update' (CAP) or 'Management Reports' (MDA) could be considered if the focus was purely financial outlook. Given the nature of announcing a partnership and product utilization, RNS is the best fit as a general regulatory/material disclosure.
2016-09-05 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references French commercial code and AMF (Autorité des Marchés Financiers) regulations, and presents a table detailing the total number of shares and theoretical voting rights as of a specific date (July 31, 2016). This content directly relates to changes in the company's capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it is a mandatory disclosure regarding the total share count. Although it is a specific type of regulatory disclosure, SHA is more precise than the general 'RNS' fallback.
2016-08-09 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Board/Management Information Classification · 98% confidence The document is a press release dated July 11, 2016, announcing the appointment of Vincent Fert to the Board of Directors of Theradiag, succeeding Jean-Paul Prieels. This content directly relates to changes in the company's governing body (Board of Directors). According to the definitions, announcements of changes in the company's board of directors or senior management fall under the 'Board/Management Information' category, which corresponds to the code MANG.
2016-07-11 French
Communicated under the obligation to provide permanent information / Other communications
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of a new individual, Vincent Fert, to the company's Board of Directors. This content directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is a press release format detailing the appointment and includes quotes from the Chairman and the new appointee.
2016-07-11 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.